Babkina Anastasiya S, Yadgarov Mikhail Ya, Ostrova Irina V, Zakharchenko Vladislav E, Kuzovlev Artem N, Grechko Andrey V, Lyubomudrov Maxim A, Golubev Arkady M
Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, 107031 Moscow, Russia.
Curr Issues Mol Biol. 2022 Oct 14;44(10):4888-4901. doi: 10.3390/cimb44100332.
Vascular endothelial growth factors (VEGFs) are important regulators of angiogenesis, neuroprotection, and neurogenesis. Studies have indicated the association of VEGF dysregulation with the development of neurodegenerative and cerebrovascular diseases. We studied the changes in serum levels of VEGF-A, VEGFR-1, and VEGFR-2 in patients at various phases of ischemic and hemorrhagic strokes. Quantitative assessment of VEGF-A, VEGFR-1, and VEGFR-2 in serum of patients with hemorrhagic or ischemic stroke was performed by enzyme immunoassay in the hyper-acute (1−24 h from the onset), acute (up to 1−7 days), and early subacute (7 days to 3 months) phases of stroke, and then compared with the control group and each other. Results of our retrospective study demonstrated different levels of VEGF-A and its receptors at various phases of ischemic and hemorrhagic strokes. In ischemic stroke, increased VEGFR-2 level was found in the hyper-acute (p = 0.045) and acute phases (p = 0.024), while elevated VEGF-A and reduced VEGFR-1 levels were revealed in the early subacute phase (p = 0.048 and p = 0.012, respectively). In hemorrhagic stroke, no significant changes in levels of VEGF-A and its receptors were identified in the hyper-acute phase. In the acute and early subacute phases there was an increase in levels of VEGF-A (p < 0.001 and p = 0.006, respectively) and VEGFR-2 (p < 0.001 and p = 0.012, respectively). Serum levels of VEGF-A and its receptors in patients with hemorrhagic and ischemic stroke indicate different pathogenic pathways depending on the phase of the disease.
血管内皮生长因子（VEGF）是血管生成、神经保护和神经发生的重要调节因子。研究表明，VEGF失调与神经退行性疾病和脑血管疾病的发生有关。我们研究了缺血性和出血性中风各阶段患者血清中VEGF-A、VEGFR-1和VEGFR-2水平的变化。采用酶免疫分析法对出血性或缺血性中风患者超急性期（发病后1 - 24小时）、急性期（最长1 - 7天）和早期亚急性期（7天至3个月）血清中的VEGF-A、VEGFR-1和VEGFR-2进行定量评估，然后与对照组进行比较，并相互比较。我们的回顾性研究结果表明，在缺血性和出血性中风的不同阶段，VEGF-A及其受体水平不同。在缺血性中风中，超急性期（p = 0.045）和急性期（p = 0.024）VEGFR-2水平升高，而在早期亚急性期VEGF-A水平升高，VEGFR-1水平降低（分别为p = 0.048和p = 0.012）。在出血性中风中，超急性期VEGF-A及其受体水平无显著变化。在急性期和早期亚急性期，VEGF-A（分别为p < 0.001和p = 0.006）和VEGFR-2（分别为p < 0.001和p = 0.012）水平升高。出血性和缺血性中风患者血清中VEGF-A及其受体水平表明，根据疾病阶段不同，其致病途径也不同。
